228 related articles for article (PubMed ID: 24386967)
1. Biomarkers of treatment response in multiple sclerosis.
Buck D; Hemmer B
Expert Rev Neurother; 2014 Feb; 14(2):165-72. PubMed ID: 24386967
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis: individualized disease susceptibility and therapy response.
Pravica V; Markovic M; Cupic M; Savic E; Popadic D; Drulovic J; Mostarica-Stojkovic M
Biomark Med; 2013 Feb; 7(1):59-71. PubMed ID: 23387485
[TBL] [Abstract][Full Text] [Related]
3. [Will multiple sclerosis (MS) susceptibility genes one day become biomarkers for MS diagnosis?].
Fontaine B
Rev Neurol (Paris); 2012 Nov; 168(11):833-5. PubMed ID: 22959703
[TBL] [Abstract][Full Text] [Related]
4. Development of biomarkers in multiple sclerosis.
Bielekova B; Martin R
Brain; 2004 Jul; 127(Pt 7):1463-78. PubMed ID: 15180926
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for multiple sclerosis.
Villoslada P
Drug News Perspect; 2010 Nov; 23(9):585-95. PubMed ID: 21152453
[TBL] [Abstract][Full Text] [Related]
6. From bench to MS bedside: challenges translating biomarker discovery to clinical practice.
Rajasekharan S; Bar-Or A;
J Neuroimmunol; 2012 Jul; 248(1-2):66-72. PubMed ID: 22381245
[TBL] [Abstract][Full Text] [Related]
7. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
Dagley LF; Emili A; Purcell AW
Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123
[TBL] [Abstract][Full Text] [Related]
8. Body fluid biomarkers for multiple sclerosis--the long road to clinical application.
Teunissen CE; Malekzadeh A; Leurs C; Bridel C; Killestein J
Nat Rev Neurol; 2015 Oct; 11(10):585-96. PubMed ID: 26392381
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
10. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pediatric multiple sclerosis and variants.
Pohl D; Waubant E; Banwell B; Chabas D; Chitnis T; Weinstock-Guttman B; Tenembaum S;
Neurology; 2007 Apr; 68(16 Suppl 2):S54-65. PubMed ID: 17438239
[TBL] [Abstract][Full Text] [Related]
12. Treatment optimisation in multiple sclerosis.
Zaffaroni M
Neurol Sci; 2005 Dec; 26 Suppl 4():S187-92. PubMed ID: 16388356
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic options in multiple sclerosis: five new things.
Miravalle A; Corboy JR
Neurology; 2010 Nov; 75(18 Suppl 1):S22-7. PubMed ID: 21041767
[No Abstract] [Full Text] [Related]
14. Immunotherapy of multiple sclerosis--current practice and future directions.
Tullman MJ; Lublin FD; Miller AE
J Rehabil Res Dev; 2002; 39(2):273-85. PubMed ID: 12051470
[TBL] [Abstract][Full Text] [Related]
15. The spectrum of multiple sclerosis and treatment decisions.
Siva A
Clin Neurol Neurosurg; 2006 Mar; 108(3):333-8. PubMed ID: 16378680
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis.
Koch MW; Metz LM; Kovalchuk O
Trends Mol Med; 2013 Jan; 19(1):23-30. PubMed ID: 23153574
[TBL] [Abstract][Full Text] [Related]
17. Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
Fawaz CN; Makki IS; Kazan JM; Gebara NY; Andary FS; Itani MM; El-Sayyed M; Zeidan A; Quartarone A; Darwish H; Mondello S
Expert Rev Proteomics; 2015; 12(6):637-50. PubMed ID: 26479122
[TBL] [Abstract][Full Text] [Related]
18. Proteomics technologies for biomarker discovery in multiple sclerosis.
Singh V; Hintzen RQ; Luider TM; Stoop MP
J Neuroimmunol; 2012 Jul; 248(1-2):40-7. PubMed ID: 22129845
[TBL] [Abstract][Full Text] [Related]
19. Neurofilaments as biomarkers in multiple sclerosis.
Teunissen CE; Khalil M
Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
[TBL] [Abstract][Full Text] [Related]
20. Overlapping and distinct mechanisms of action of multiple sclerosis therapies.
Graber JJ; McGraw CA; Kimbrough D; Dhib-Jalbut S
Clin Neurol Neurosurg; 2010 Sep; 112(7):583-91. PubMed ID: 20627553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
